Home
/
Elicio Therapeutics, Inc.
/
Financials
/
Quarterly
Elicio Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Elicio Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2023
Mar 31, 2023
$0
May 10, 2023
Q3
2022
Sep 30, 2022
$0
Nov 14, 2022
Q2
2022
Jun 30, 2022
$653.0K
Aug 15, 2022
Q1
2023
Mar 31, 2022
$1.65M
May 10, 2023
Q3
2022
Sep 30, 2021
$1.46M
Nov 14, 2022
Q2
2022
Jun 30, 2021
$540.0K
Aug 15, 2022
Q1
2022
Mar 31, 2021
$371.0K
May 16, 2022
Q3
2021
Sep 30, 2020
$827.0K
Nov 12, 2021
Q2
2021
Jun 30, 2020
$729.0K
Aug 12, 2021
Q1
2021
Mar 31, 2020
$865.0K
May 17, 2021
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($10.08M)
Nov 13, 2025
Q3
2025
Jun 30, 2025
($10.56M)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($10.56M)
Aug 7, 2025
Q2
2025
Mar 31, 2025
($11.21M)
Aug 7, 2025
Q3
2025
Mar 31, 2025
($11.21M)
Nov 13, 2025
Q1
2025
Mar 31, 2025
($11.21M)
May 13, 2025
Q3
2025
Sep 30, 2024
($18.84M)
Nov 13, 2025
Q3
2025
Jun 30, 2024
($7.23M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($7.23M)
Aug 7, 2025
Q3
2025
Mar 31, 2024
($11.83M)
Nov 13, 2025
Q1
2025
Mar 31, 2024
($11.83M)
May 13, 2025
Q2
2025
Mar 31, 2024
($11.83M)
Aug 7, 2025
Q3
2024
Sep 30, 2023
($10.66M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
($7.56M)
Aug 13, 2024
Q3
2024
Jun 30, 2023
($7.56M)
Nov 13, 2024
Q1
2024
Mar 31, 2023
($8.03M)
May 15, 2024
Q3
2024
Mar 31, 2023
($8.03M)
Nov 13, 2024
Q2
2024
Mar 31, 2023
($8.03M)
Aug 13, 2024
Q3
2023
Sep 30, 2022
($7.20M)
Nov 13, 2023
Q3
2023
Jun 30, 2022
($7.30M)
Nov 13, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($8.05M)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($10.09M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($10.74M)
May 13, 2025
Q3
2025
Sep 30, 2024
($10.34M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($10.92M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($10.24M)
May 13, 2025
Q3
2024
Sep 30, 2023
($10.77M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
($7.78M)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($7.81M)
May 15, 2024
Q3
2023
Sep 30, 2022
($5.77M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($6.23M)
Aug 14, 2023
Q1
2023
Mar 31, 2022
($14.49M)
May 10, 2023
Q3
2022
Sep 30, 2021
($15.76M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($18.24M)
Aug 15, 2022
Q1
2022
Mar 31, 2021
($19.94M)
May 16, 2022
Q3
2021
Sep 30, 2020
($11.59M)
Nov 12, 2021
Q2
2021
Jun 30, 2020
($17.27M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($12.57M)
May 17, 2021